- Home
- OKYO vs PLRX Comparison
OKYO vs PLRX Comparison
Compare OKYO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- PLRX
- Stock Information
- Founded
- OKYO 2007
- PLRX 2015
- Country
- OKYO United Kingdom
- PLRX United States
- Employees
- OKYO N/A
- PLRX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- PLRX Health Care
- Exchange
- OKYO Nasdaq
- PLRX Nasdaq
- Market Cap
- OKYO 97.8M
- PLRX 93.3M
- IPO Year
- OKYO 2022
- PLRX 2020
- Fundamental
- Price
- OKYO $2.22
- PLRX $1.63
- Analyst Decision
- OKYO Strong Buy
- PLRX Hold
- Analyst Count
- OKYO 1
- PLRX 11
- Target Price
- OKYO $7.00
- PLRX $3.79
- AVG Volume (30 Days)
- OKYO 136.7K
- PLRX 941.3K
- Earning Date
- OKYO 07-18-2025
- PLRX 11-06-2025
- Dividend Yield
- OKYO N/A
- PLRX N/A
- EPS Growth
- OKYO N/A
- PLRX N/A
- EPS
- OKYO N/A
- PLRX N/A
- Revenue
- OKYO N/A
- PLRX N/A
- Revenue This Year
- OKYO N/A
- PLRX N/A
- Revenue Next Year
- OKYO N/A
- PLRX N/A
- P/E Ratio
- OKYO N/A
- PLRX N/A
- Revenue Growth
- OKYO N/A
- PLRX N/A
- 52 Week Low
- OKYO $0.90
- PLRX $1.10
- 52 Week High
- OKYO $3.35
- PLRX $15.80
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- PLRX 49.41
- Support Level
- OKYO $2.33
- PLRX $1.45
- Resistance Level
- OKYO $2.93
- PLRX $1.82
- Average True Range (ATR)
- OKYO 0.22
- PLRX 0.12
- MACD
- OKYO -0.05
- PLRX -0.00
- Stochastic Oscillator
- OKYO 10.46
- PLRX 53.42
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.